Product Information
VENLAFAXINE HCL ER 37.5 MG CAP is a generic product labeled by Quallent Pharmaceuticals Health LLC, priced at $0.0791 per EA under NDC 82009005610. Its NADAC has been published 178 times since May 10, 2023.
FDA first approved this application on Apr 14, 2011. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
37.5 mg/1
Manufacturer
Quallent Pharmaceuticals Health LLCNDC
82009005610
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
VENLAFAXINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA200834FDA Approved
4/14/2011
TE Code
AB
On Market Since
11/21/2022
Pharmacological Classes
Price Statistics
The NADAC for VENLAFAXINE HCL ER 37.5 MG CAP has been published 178 times since May 10, 2023, and over the history we have for it it has declined 15.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0791 per EA |
|---|---|
| All-time high | $0.1079 (Aug 16, 2023) |
| All-time low | $0.0712 (Nov 20, 2024) |
| 52-week high | $0.0909 |
| 52-week low | $0.0791 |
| Median price | $0.0908 |
| Average price | $0.0909 |
| Largest weekly change | +28.7% (Aug 21, 2024) |
| Weeks tracked | 178 |
| Tracking since | May 10, 2023 |
Generic Alternatives
The matcher finds 8 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Quallent Pharmaceuticals Health LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Venlafaxine Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin and Norepinephrine Reuptake Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of VENLAFAXINE HCL ER 37.5 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for VENLAFAXINE HCL ER 37.5 MG CAP, manufactured by Quallent Pharmaceuticals Health LLC, is $0.0791 per EA (NDC 82009005610), effective Sep 30, 2026.
How has the price of VENLAFAXINE HCL ER 37.5 MG CAP changed over time?
Over the history we have for it, the NADAC for VENLAFAXINE HCL ER 37.5 MG CAP has declined 15.9%. It has been tracked across 178 weekly CMS publications since May 10, 2023.
What are the highest and lowest recorded NADAC prices for VENLAFAXINE HCL ER 37.5 MG CAP?
Since May 10, 2023, the NADAC for VENLAFAXINE HCL ER 37.5 MG CAP has ranged from a low of $0.0712 (Nov 20, 2024) to a high of $0.1079 (Aug 16, 2023), with a median of $0.0908 per EA.
Are there cheaper alternatives to VENLAFAXINE HCL ER 37.5 MG CAP?
8 manufacturers publish a NADAC-priced product with the same active ingredient and strength as VENLAFAXINE HCL ER 37.5 MG CAP in a comparable dosage form, but none are currently priced below it.
Who manufactures VENLAFAXINE HCL ER 37.5 MG CAP?
VENLAFAXINE HCL ER 37.5 MG CAP (NDC 82009005610) is labeled by Quallent Pharmaceuticals Health LLC, and CMS classifies it as a generic product.